BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28421466)

  • 1. Parathyroid Diseases and T Cells.
    Neale Weitzmann M; Pacifici R
    Curr Osteoporos Rep; 2017 Jun; 15(3):135-141. PubMed ID: 28421466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells potentiate PTH-induced cortical bone loss through CD40L signaling.
    Gao Y; Wu X; Terauchi M; Li JY; Grassi F; Galley S; Yang X; Weitzmann MN; Pacifici R
    Cell Metab; 2008 Aug; 8(2):132-45. PubMed ID: 18680714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss.
    Tawfeek H; Bedi B; Li JY; Adams J; Kobayashi T; Weitzmann MN; Kronenberg HM; Pacifici R
    PLoS One; 2010 Aug; 5(8):e12290. PubMed ID: 20808842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone and the Immune System.
    Weitzmann MN
    Toxicol Pathol; 2017 Oct; 45(7):911-924. PubMed ID: 29046115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?
    Van Bezooijen RL; Papapoulos SE; Löwik CW
    Bone; 2001 Apr; 28(4):378-86. PubMed ID: 11336918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
    O'Brien CA; Jilka RL; Fu Q; Stewart S; Weinstein RS; Manolagas SC
    Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E784-93. PubMed ID: 15956054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
    Yang Y; Blair HC; Shapiro IM; Wang B
    J Biol Chem; 2015 Jul; 290(27):16918-28. PubMed ID: 25979341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-17 Receptor Signaling in Osteoblasts/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production.
    Li JY; Yu M; Tyagi AM; Vaccaro C; Hsu E; Adams J; Bellido T; Weitzmann MN; Pacifici R
    J Bone Miner Res; 2019 Feb; 34(2):349-360. PubMed ID: 30399207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.
    Li Y; Toraldo G; Li A; Yang X; Zhang H; Qian WP; Weitzmann MN
    Blood; 2007 May; 109(9):3839-48. PubMed ID: 17202317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
    Romas E; Gillespie MT; Martin TJ
    Bone; 2002 Feb; 30(2):340-6. PubMed ID: 11856640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
    Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
    J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D and bone.
    Suda T; Ueno Y; Fujii K; Shinki T
    J Cell Biochem; 2003 Feb; 88(2):259-66. PubMed ID: 12520524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures.
    Lee SK; Lorenzo JA
    Bone; 2002 Jul; 31(1):252-9. PubMed ID: 12110442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone and its related peptides in bone metabolism.
    Chen T; Wang Y; Hao Z; Hu Y; Li J
    Biochem Pharmacol; 2021 Oct; 192():114669. PubMed ID: 34224692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells.
    Toraldo G; Roggia C; Qian WP; Pacifici R; Weitzmann MN
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):125-30. PubMed ID: 12490655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.